Abstract
Due to eutrophication processes in our water bodies, cyanobacterial blooms can develop worldwide. Most of these blooms are toxic. The most prominent cyanobacterial toxins are the group of the microcystins, which are cyclic heptapeptides, currently with more than 100 congeners known. The biotransformation of microcystins starts with the conjugation to the cell internal tripeptide glutathione, catalysed by glutathione S-transferase enzymes. This conjugate is further broken down to a cysteine conjugate, enhancing the cell internal transport and excretion of the conjugated toxin from the organisms. Still many questions remain open, thinking on an obviously good working detoxification system on the one side and the often seen negative effects up to the death of humans on the other sides.
Keywords: Biotransformation, Metabolism, Microcystins, Phase I and Phase II.
Mini-Reviews in Medicinal Chemistry
Title:Biotransformation of Microcystins in Eukaryotic Cells - Possible Future Research Directions
Volume: 16 Issue: 13
Author(s): Stephan Pflugmacher
Affiliation:
Keywords: Biotransformation, Metabolism, Microcystins, Phase I and Phase II.
Abstract: Due to eutrophication processes in our water bodies, cyanobacterial blooms can develop worldwide. Most of these blooms are toxic. The most prominent cyanobacterial toxins are the group of the microcystins, which are cyclic heptapeptides, currently with more than 100 congeners known. The biotransformation of microcystins starts with the conjugation to the cell internal tripeptide glutathione, catalysed by glutathione S-transferase enzymes. This conjugate is further broken down to a cysteine conjugate, enhancing the cell internal transport and excretion of the conjugated toxin from the organisms. Still many questions remain open, thinking on an obviously good working detoxification system on the one side and the often seen negative effects up to the death of humans on the other sides.
Export Options
About this article
Cite this article as:
Pflugmacher Stephan, Biotransformation of Microcystins in Eukaryotic Cells - Possible Future Research Directions, Mini-Reviews in Medicinal Chemistry 2016; 16 (13) . https://dx.doi.org/10.2174/1389557516666160219130837
DOI https://dx.doi.org/10.2174/1389557516666160219130837 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry Aryltetralin-type Lignan of Podophyllum: A Comprehensive Review
The Natural Products Journal Autism, Mitochondria and Polybrominated Diphenyl Ether Exposure
CNS & Neurological Disorders - Drug Targets Small Molecules for Immunomodulation in Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Hyperglycemia, Hypoglycemia and Dementia: Role of Mitochondria and Uncoupling Proteins
Current Molecular Medicine Engagement of Renin-Angiotensin System in Prostate Cancer
Current Cancer Drug Targets Assessment of Signal Peptides to Optimize Interleukin 2 (IL-2) Folding and Expression
Current Proteomics Development of Anti-HIV Agents Targeting Dynamic Supramolecular Mechanism: Entry and Fusion Inhibitors Based on CXCR4/CCR5 Antagonists and gp41-C34-Remodeling Peptides
Current HIV Research The Contribution of Extracellular Nef to HIV-Induced Pathogenesis
Current Drug Targets Human Imprinting Anomalies in Fetal and Childhood Growth Disorders: Clinical Implications and Molecular Mechanisms
Current Pharmaceutical Design Alternative Splice Variants of Survivin as Potential Targets in Cancer
Current Drug Discovery Technologies Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Implication of Possible Therapies Targeted for the Tachykinergic System with the Biology of Neurokinin Receptors and Emerging Related Proteins
Recent Patents on CNS Drug Discovery (Discontinued) Regulatory Triangle of Neurodegeneration, Adult Neurogenesis and MicroRNAs
CNS & Neurological Disorders - Drug Targets Estrogen Receptor Modulators: Relationships of Ligand Structure, Receptor Affinity and Functional Activity
Current Topics in Medicinal Chemistry Tumour Re-Differentiation Effect of Retinoic Acid: A Novel Therapeutic Approach for Advanced Thyroid Cancer
Current Pharmaceutical Design Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Current Pharmaceutical Design Indolo[2,3-a]quinolizidines and Derivatives: Bioactivity and Asymmetric Synthesis
Current Pharmaceutical Design The Role of Neuronal Insulin/Insulin-Like Growth Factor-1 Signaling for the Pathogenesis of Alzheimer’s Disease: Possible Therapeutic Implications
CNS & Neurological Disorders - Drug Targets Iron Chelators in Medicinal Applications - Chemical Equilibrium Considerations in Pharmaceutical Activity
Current Medicinal Chemistry